Illumina’s Pan-Cancer Companion Diagnostic to Match Patients to Targeted Therapy
Illumina, a provider in DNA sequencing and array-based technologies, announced the addition of a...
Read MorePosted by Andy Lundin | May 25, 2022 | Cancer |
Illumina, a provider in DNA sequencing and array-based technologies, announced the addition of a...
Read MorePosted by Andy Lundin | May 25, 2022 | Allergy & Autoimmune, Diagnostic Technologies |
A next-gen sequencing test is facilitating treatment options and earlier diagnosis in family members who inherited a genetic abnormality.
Read MorePosted by Andy Lundin | May 24, 2022 | Diabetes & Metabolic Diseases |
The American Liver Foundation announced a screening and public awareness campaign to test for fatty liver disease over the next five years.
Read MorePosted by Andy Lundin | May 20, 2022 | Cancer |
Researchers identified cancer biomarkers based on a type of genetic modification that predicts the type of tumor immune environment and patient outcomes.
Read MorePosted by Chris Wolski | May 20, 2022 | Covid 19, Emerging & Zoonotic Diseases |
A clear set of pandemic prevention and preparedness strategies will be critical for clinical labs to meet the challenges the next event.
Read More